##plugins.themes.bootstrap3.article.main##

Background: Heart failure (HF) is the inability of the heart to pump blood to meet tissue requirement of oxygen and nutrition, due to abnormality in cardiac structure or function. The mortality from congestive heart failure remain increasing along with aging of the population. In Oman, the prevalence of HF is 5.17 per 1000 people and with male and older age group domination. Beta-blockers and diuretics are well known drugs that decrease mortality and morbidity. According to heart failure treating guidelines beta-blockers are the first line treatment for HF. Since HF has a high prevalence, this study aim was to determine the utilization of beta-blockers and diuretics in treating heart failure patients in Sultan Qaboos University Hospital (SQUH). Methods: A retrospective cross-sectional conducted in SQUH, in cardiology day care clinic in the period from 1st of June until 30th of August. This study included all Omani patients with 120 out of 778 patients were included who were above 18 years old, diagnosed with HF, receiving at least one HF medication from SQUH pharmacy, and did not have any missing data. Hospital electronic medical record was used to obtain patients data and parameters. Results: Out of 120 patients, 54.2% were males and 45.8% were females, with mean age equal to 64 ± 13 years and mean EF equal to 37 ± 14.5 %. Diuretics were taken by 95% of the patients, where beta-blockers were taken by 81.6%. Prescription of beta-blockers was significantly decreased by increase in the age of the patients (p =0.024), while diuretics do not show any significant with change in the age. Both beta-blockers and diuretics do not show any significant increase or decrease in prescription with change in the EF. Bisoprolol was not affected by increase in age or EF. The prescription of carvedilol was significantly affected with increase the age (p = 0.006), however it was not affected by increase the EF. The prescription of spironolactone was significantly affected by increase the age (P= 0.001) and by increase the EF (P = 0.001). Conclusion: Carvedilol and furosemide were the most prescribed drugs in SQUH for treating HF patients. All the mean daily doses of the drugs mentioned in this study followed the newer 2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic HF.

Downloads

Download data is not yet available.

References

  1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Heart Journal Advance Access published June 8, 2016.
     Google Scholar
  2. A National Clinical Guideline. SIGN 147; Management of chronic heart failure; 2016; 18-23.
     Google Scholar
  3. Agarwal AK, Venugopalan P, de Bono D. Prevalence and etiology of heart failure in an Arab population. Eur J Heart Failure 2001; 3: 301-305.
    DOI  |   Google Scholar
  4. Al-Shamiri MQ. Heart Failure in the Middle East. Current Cardiology Reviews, 2013, 9, 174-178.
    DOI  |   Google Scholar
  5. British National Formular; 2015.
     Google Scholar
  6. Bruns LA, Carter CE (2002) Should B-blockers be used for the treatment of pediatric patients with chronic heart failure? Pediatr Drugs 4:771–778.
    DOI  |   Google Scholar
  7. Dickstein K, Cohen-Solal A, Filippatos G. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2008; 29: 2388–442.
    DOI  |   Google Scholar
  8. Doba N, Tomiyama H, Nakayama T. Drugs, Heart Failure and Quality of Life. Drugs & Aging 1999 Mar; 14 (3): 153-163.
    DOI  |   Google Scholar
  9. He, Y., Yang, X., Zhao, X., Cheng, X., Xu, H., Qian, Y. and Li, X. β-Blockers in Heart Failure: Benefits of β-Blockers according to varying male proportions of study patients. Clin Cardiol, 2012; 35(8):505-511.
    DOI  |   Google Scholar
  10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC, Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circula- tion 2005; 112:e154–235.
    DOI  |   Google Scholar
  11. Laer S, Mir TS, Behn F et al (2002) Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143(5):916–922.
    DOI  |   Google Scholar
  12. Levy E. & LevyP. Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies. Pharmacoeconomics 2002; 20 (14): 963-977.
    DOI  |   Google Scholar
  13. Liu F, Chen Y, Feng X, et al. Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis, 2014; PLoS ONE 9(3): e90555.
    DOI  |   Google Scholar
  14. McMurray JJV; Adamopoulos S; Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012, The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardi- ology. European Heart Journal 2012; 33: 1787-1847.
    DOI  |   Google Scholar
  15. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146.
    DOI  |   Google Scholar
  16. Nicholson C.Chronic heart failure: pathophysiology, diagnosis and treatment. Nursing Older People.2014; 26, 7, 29-38.
    DOI  |   Google Scholar
  17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart fail- ure. N Engl J Med 1996; 334:1349–1355.
    DOI  |   Google Scholar
  18. Rang HP, Dale MM, Ritter JM. Pharmacology, 7th Edition. Churchill Livingstone, Edinburgh 2011.
     Google Scholar
  19. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997; 45:968-974.
    DOI  |   Google Scholar
  20. Shihmanter R, Nulman I, Goland S, et al. Pharmacogenetics: Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure. Journal of Clinical Pharmacy and Therapeutics, 2014; 39;432–438.
    DOI  |   Google Scholar
  21. Trobec C, Grabnar1 I, Kos K, et al. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol, 2016; 72:813–822.
    DOI  |   Google Scholar
  22. Westfall TC, Westfall DP (2011) Adrenergic agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman and Gilman’s the phar- macological basis of therapeutics, 12th edn. McGraw- Hill, New York.
     Google Scholar
  23. Xiang S, Zhang N, Yang Z, et al. Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload‑induced cardiac hypertrophy and fibrosis. Experimental And Therapeutic Medicine, 2016; 12: 2027-2038.
    DOI  |   Google Scholar


Most read articles by the same author(s)